Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.
Sign Up to like & getrecommendations! Published in 2023 at "Modern rheumatology"
DOI: 10.1093/mr/road031
Abstract: OBJECTIVE We compared the incidence rates of hospitalized infections (HIs) between tocilizumab (TCZ) and other biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in adults aged ≥75 years with rheumatoid arthritis (RA). METHODS We used a Japanese claims… read more here.
Keywords: synthetic disease; risk; hospitalized infections; biological targeted ... See more keywords
Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13244
Abstract: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease‐modifying anti rheumatic drugs (csDMARDs) on patient‐reported outcomes in Chinese patients with… read more here.
Keywords: tofacitinib conventional; conventional synthetic; disease modifying; synthetic disease ... See more keywords